Aventis Lovenox patents
Executive Summary
Aventis will not file patent infringement lawsuit against Amphastar to enforce Lovenox patent No. 4,692,435, set to expire in December 2004. Aventis' defense against enoxaparin generics is focused on the re-issuance of another patent (No. 5,389,618) that will expire in February 2012. The company received a 30-month stay of approval based on a suit against Amphastar and Teva on the original '618 patent (1"The Pink Sheet" Aug. 18, 2003, p. 16)...